Macrocytic Anemia and Thrombocytopenia Induced by Orlistat

AuthorDavid Palacios-Martinezen
AuthorJuan Carlos Garcia-Alvarezen
AuthorNieves Montero-Santamariaen
AuthorOlga Patricia Villar-Ruizen
AuthorAntonio Ruiz-Garciaen
AuthorRaquel Asuncion Diaz-Alonsoen
Issued Date2013-09-01en
AbstractIntroduction:: The overall incidence of obesity and its prevalence is increasing continuously. The obesity is a cardiovascular risk factor whose importance is increasing too. It is associated with many chronic conditions such as type II diabetes mellitus or cardiovascular diseases. The obesity is also implicated as a risk factor for several kinds of cancer such as esophagus, pancreas, colon, rectum, breast cancer in menopausal women. The treatment of the obesity may reduce the incidence of these diseases. The mainstray of the treatment of obesity is changing the lifestyles, but obesity´s treatment may need drug therapy or even though surgical treatment. Case Report:: Besides the interaction with other drugs (mainly warfarin and amiodarone). Discussion:: In this case report appears a new adverse effect of Orlistat that has not been described above: thrombopenia and macrocytic anemia.en
DOIhttps://doi.org/10.5812/ijem.6721en
KeywordAnti-Obesity Agentsen
KeywordObesityen
KeywordMorbiden
KeywordThrombocytopeniaen
PublisherBrieflandsen
TitleMacrocytic Anemia and Thrombocytopenia Induced by Orlistaten
TypeCase Reporten

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
17618-pdf.pdf
Size:
212.6 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF